U.S. markets closed

Teleflex Incorporated (TFX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
351.46-5.90 (-1.65%)
At close: 4:04PM EDT

351.46 0.00 (0.00%)
After hours: 4:40PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close357.36
Open357.00
Bid351.72 x 900
Ask352.10 x 800
Day's Range350.75 - 357.05
52 Week Range221.27 - 409.27
Volume225,790
Avg. Volume214,910
Market Cap16.349B
Beta (5Y Monthly)1.03
PE Ratio (TTM)34.60
EPS (TTM)10.16
Earnings DateOct 29, 2020
Forward Dividend & Yield1.36 (0.38%)
Ex-Dividend DateAug 13, 2020
1y Target Est428.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
2% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Teleflex Delivers COMPLETE Confidence with  the New Arrow® ErgoPack® Complete CVC System
    GlobeNewswire

    Teleflex Delivers COMPLETE Confidence with the New Arrow® ErgoPack® Complete CVC System

    Most important CVC update in a decade adds a variety of clinician-inspired enhancementsWAYNE, Pa., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) delivers COMPLETE confidence to central line inserters with the release of the Arrow® ErgoPack® Complete CVC System, the most important update to its market-leading1 portfolio of Centrally-Inserted Central Catheters in more than a decade.Teleflex conducted extensive research with industry-leading vascular access professionals to select the enhancements in the new ErgoPack® Complete System. Clinician-inspired updates to the kit include: * The Arrow GlideWheel™ Advancer, which provides tactile feedback and finer control * Nitinol Guidewire, which is kink-resistant compared to stainless steel * Transducer Cover to support guidelines for ultrasound use * Pre-filled sterile saline syringes, one per catheter lumen * Extra ChloraPrep® Skin Prep in each kit (two total)“The ErgoPack® Complete System is built with the inserter in mind, first and foremost,” said Jake Newman, President and General Manager, Teleflex Vascular. “The ErgoPack® Complete System is a powerful tool in the fight against CLABSI.1”These new additions enhance the already-considerable power of the market-leading2 ErgoPack® System, which features, at its heart, Teleflex’s Arrowg+ard Blue Plus® CVC. It’s the only full-spectrum antimicrobial CVC that protects against gram-positive, gram-negative bacteria and fungi, the key infectious pathogens responsible for CLABSI.CLABSI is responsible for as many as 28,000 deaths per year in the US.3The ErgoPack® Complete System’s unique combination of CVC insertion components, packaged in an ergonomic and efficient top down, left to right configuration, helps central line inserters comply with critical third party independent guidelines for reducing CLABSI, including: * Centers for Disease Control and Prevention (CDC) Category 1A & 1B recommendations4 * Society for Hospital Epidemiology of America (SHEA) Guidelines5 * Infusion Nursing Society (INS) Standards of Practice6 * Occupational Health and Safety Administration (OSHA) Bloodborne Pathogens Standard7The ErgoPack® Complete System is available in two different configurations, in a variety of catheter French sizes. Learn more at http://go.teleflex.com/CompleteConfidenceAbout Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.Rx only Contraindication: The Arrowg+ard Blue Plus® CVC is contraindicated for patients with known hypersensitivity to chlorhexidine and silver sulfadiazine and/or sulfa drugs.Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Plus, Deknatel, ErgoPack, GlideWheel, Hudson RCI, LMA, Pilling, Rusch, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners. © 2020 Teleflex Incorporated. All rights reserved. MC-006733References: 1. 1\. Raad, II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infection Control and Hospital Epidemiology. 1994;15(4 Pt 1): 231-238. 2. DRG data. Teleflex. 2020. 3. https://www.ahrq.gov/topics/central-line-associated-bloodstream-infections-clabsi.html 4. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011 (Revised 2017). 2. Atlanta, GA: Centers for Disease Control and Prevention; 2017. 5. Marschall J, Mermel LA, Fakih M, et al. Strategies to Prevent Central Line–Associated Bloodstream Infections in Acute Care Hospitals: 2014 Update. Infection Control and Hospital Epidemiology. 2014 July; 35(7): 753-71. 6. Gorski L, Hadaway L, Hagle ME, McGoldrick M, et al. Infusion Therapy Standards of Practice. Journal of Infusion Nursing. 2016; Jan 39(1S). 7. Occupational Safety & Health Administration Regulations (Standards – 29 CFR). Part 1910.1030: Bloodborne pathogens. Occupational Safety & Health Administration Web site. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030. Accessed on February 12, 2020. Source: Teleflex Incorporated Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836

  • Earnings Preview: Teleflex (TFX) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Teleflex (TFX) Q3 Earnings Expected to Decline

    Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Teleflex Announces Third Quarter 2020 Earnings Conference Call Information

    Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, October 29, 2020WAYNE, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that financial results for the third quarter 2020 will be released before market open on Thursday, October 29, 2020. An investor conference call will be held at 8:00 a.m. (ET) on Thursday, October 29, 2020. The call can be accessed through a live audio webcast on the company’s website, www.teleflex.com. An audio replay of the call will also be available on the website from October 29, 2020 at 11:00 a.m. (ET) to November 3, 2020 at 11:00 a.m. (ET) by calling 855-859-2056 (U.S./Canada) or 404-537-3406 (International), Conference ID number: 4987865. About Teleflex Incorporated Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.Source: Teleflex Incorporated Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836